3 citations · 4 across the 4 of their papers we have counts for
4 papers
Chasing Shadows: How Implausible Assumptions Skew Our Understanding of Causal Estimands
Stijn Vansteelandt, Kelly Van Lancker
The ICH E9 (R1) addendum on estimands, coupled with recent advancements in causal inference, has prompted a shift towards using model-free treatment effect estimands that are more…
Estimands and their Estimators for Clinical Trials Impacted by the COVID-19 Pandemic: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions
Kelly Van Lancker, Sergey Tarima, Jonathan Bartlett +8
The COVID-19 pandemic continues to affect the conduct of clinical trials globally. Complications may arise from pandemic-related operational challenges such as site closures, trave…
Efficient, Doubly Robust Estimation of the Effect of Dose Switching for Switchers in a Randomised Clinical Trial
Kelly Van Lancker, An Vandebosch, Stijn Vansteelandt
Motivated by a clinical trial conducted by Janssen Pharmaceuticals in which a flexible dosing regimen is compared to placebo, we evaluate how switchers in the treatment arm (i.e.,…
Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?
Cornelia Ursula Kunz, Silke Jörgens, Frank Bretz +6
Very recently the new pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified and the coronavirus disease 2019 (COVID-19) declared a pandemic by the Wo…